Visit our virtual booth at the 23rd Annual John Goldman e-Conference on Chronic Myeloid Leukemia to learn more about our QuantideX® qPCR BCR-ABL portfolio.
Targeted therapies have dramatically improved outcomes for patients with CML, who now experience a near-normal life expectancy. Optimizing these outcomes is dependent on routine, sensitive molecular monitoring.
For clinicians and their patients, the best molecular results are delivered by tests with a demonstrated track record of performance. The QuantideX® qPCR BCR-ABL IS1 2 and minor Kits1 3 enable quantification of Major (e13a2, e14a2) and minor (e1a2) BCR-ABL1 mRNA transcripts with highly sensitive, accurate, and precise results.
QuantideX qPCR BCR-ABL IS Kit and ipsogen BCR-ABL1 Mbcr IS-MMR Kit Yield Highly Correlated Results
Justin Brown, PhD, Principal Scientist, Asuragen
QuantideX® qPCR BCR ABL IS Kit Website
QuantideX® qBCR BCR-ABL minor Kit Website
Enhancing Management of Ph+ ALL by Monitoring with an Analytically Validated Multiplex Assay for BCR-ABL1 minor Breakpoint (e1a2) with Highly Sensitive Detection of 1:40,000 (0.0025% or 4.6 Logs)
Validation of a Complete Solution for BCR-ABL1 Monitoring of Both Major and Minor Breakpoints that Reports ABL1 Copy Number
Validation of BCR-ABL1 Test Performance from Whole Blood Stored up to 72 Hours Facilitates Operational Flexibility and Expanding Locally Managed CML Monitoring
J Mol Diagn. 2019 Jul;21(4):718-733. Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA
Developments in CML Patient Management and its Impact on Monitoring: Analytical Validation of a BCR-ABL 1 Monitoring System that Surpasses Current Testing Requirements
Check-In Time for Cancer Screening (The Pathologist)
1 CE-IVD for US export only | 2 FDA-cleared for in vitro diagnostic use | 3 For Research Use Only. Not for use in diagnostic procedures.